Efeito da adição de trolox e pentoxifilina na motilidade, integridade do acrossoma e do DNA de espermatozoides equinos após descongelação / Effect of trolox and pentoxifylline on motility and integrity of, acrossome and DNA of equine spermatozoa after thawing

Três garanhões foram utilizados para estudar o efeito da adição de trolox e pentoxifilina na motilidade, integridade do acrossoma e DNA de espermatozoides pós-descongelação. Para congelação, utilizou-se Tris-gema com glicerol (5 por cento) em máquina de congelação de sêmen. As amostras foram descongeladas a 37ºC durante 30 segundos e tratadas com: T1= 150µL de sêmen + 150µL de Tris; T2= 150µL de sêmen + 150µL de Tris + 120µM/mL de trolox; T3= 150µL de sêmen + 150µL de Tris + 3,5mM de pentoxifilina e T4= 150µL de sêmen + 150µL de Tris + 3,5mM de pentoxifilina + 120µM/mL de trolox. Após 0, 60 e 120 minutos de incubação (37ºC), as amostras foram analisadas quanto à motilidade, vigor, integridade de acrossoma e DNA. Não houve diferença (P>0,05) entre tratamentos após 0 e 60 minutos de incubação em todos os parâmetros estudados. Após 120 minutos de incubação, verificou-se maior porcentual (P<0,05) de células com motilidade total e progressiva nas amostras do T2. Conclui-se que a adição de trolox após descongelação do sêmen equino preserva a motilidade total e progressiva dos espermatozoides submetidos à incubação a 37ºC durante 120 minutos.

Three stallions were used to study the effect of trolox and pentoxifylline addition on the motility and integrity of acrossome and DNA equine spermatozoa after thawing. Tris-egg-yolg diluent with glycerol (5 percent) were used to freeze the semen samples in a freezing machine. The samples were thawed at 37ºC during 30 seconds and treated with: T1=150µL of semen + 150µL of Tris; T2= 150µL of semen + 150µL of Tris +150mM/mL of trolox; T3= 150µL of semen + 150µL Tris +3.5mM of pentoxifylline; and T4= 150µL of semen + 150µL of Tris + 3.5mM of pentoxifylline + 150mM of trolox. After 0, 60, and 120 minutes of incubation (37ºC), the samples were analyzed to motility, vigor, and integrity of acrossome and DNA. There was no difference (P>0.05) among treatments considering 0 and 60 minutes of incubation in all studied parameters. After 120 minutes of incubation, it was observed higher percentage (P<0.05) of cells with total and progressive motility in the samples of T2. It can be concluded that the trolox addition after thawing of equine semen preserved total and progressive motility of the sperm incubated at 37ºC during 120 minutes.

Efeito do uso de pentoxifilina no período neonatal sobre a produção espermática em ratos Wistar adultos / Effect of pentoxifylline during neonatal period on spermatic production in adult Wistar rats

Utilizaram-se doses crescentes de pentoxifilina em ratos Wistar neonatos visando aumentar a produção espermática em animais adultos. Trinta e sete animais foram distribuídos de acordo com os tratamentos: não tratados (n=10) e tratados com 1mg/kg (n=10), 5mg/kg (n=9) e 10mg/kg (n=8) de pentoxifilina (IP). Aos 90 dias, os animais foram anestesiados e perfundidos intracardiacamente com solução fixadora. Os testículos foram processados rotineiramente para inclusão em resina plástica à base de glicol metacrilato. Cortes histológicos de 4µm de espessura foram corados em azul de toluidina/borato de sódio a 1 por cento e analisados histometricamente. O número de células de Sertoli por secção transversal diminuiu nos grupos tratados com 5mg/kg e 10mg/kg em relação aos grupos controle e tratado com 1mg/kg. O índice de células de Sertoli aumentou nos animais tratados com 5mg/kg em comparação aos do grupo-controle. A utilização da pentoxifilina não foi capaz de induzir aumento na população das células de Sertoli e produção espermática em ratos adultos.

Increasing doses of pentoxifylline were administrated to newborn Wistar rats in order to augment Sertoli cell number and sperm production in the adult rats. Thirty-seven neonate Wistar rats were distributed in four groups: control (n=10) and treated with 1mg/kg (n=10), 5mg/kg (n=9), and 10mg/kg (n=8) of pentoxifylline. At 90 days, the animals were submitted to anesthesia and intracardiac perfusion. Testes were colleted and routinely processed for inclusion in plastic resin with glycol methacrylate. Histological sections (4µm) were stained in toluidine blue/sodium borate (1 percent) and analyzed. Number of Sertoli cell per transversal section of seminiferous tubule had significant reduction in the groups treated with 5mg/kg and 10mg/kg of pentoxifylline as compared to control and the group that received 1mg/kg (P<0.05). The Sertoli cell index significantly increased in the group treated with 5mg/kg compared to control group. Pentoxifylline did not cause increase in the number of Sertoli cells and daily sperm production in adult male rats.

Systemic treatment in severe cases of recurrent aphthous stomatitis: an open trial

PURPOSE: This study aimed to evaluate the efficacy of the systemic drugs thalidomide, dapsone, colchicine, and pentoxifylline in the treatment of severe manifestations of RAS. METHODS: An open, 4-year clinical trial was carried out for 21 consecutive patients with severe RAS. Initially, patients were given a 2-week course of prednisone to bring them to a baseline status. Simultaneously, one of the four test drugs was assigned to each patient to be taken for a period of 6 months. During the course of the trial, patients were switched to one of the other three drugs whenever side effects or a lack of satisfactory results occurred, and the 6-month limit of the treatment was then reset. RESULTS: The most efficient and best-tolerated drug was thalidomide, which was administered to a total of eight patients and resulted in complete remission in seven (87.5 percent). Dapsone was prescribed for a total of nine patients, of whom eight (89 percent) showed improvement in their symptoms, while five showed complete remission. Colchicine was administered to a total of ten patients, with benefits observed in nine (90 percent), of whom four showed complete remission. Pentoxyfilline was administered to a total of five patients, with benefits observed in three (60 percent), of whom one patient showed complete remission. CONCLUSION: The therapeutic methods used in this trial provided significant symptom relief. Patients experienced relapses of the lesions; however, this occurred after withdrawal of their medication during the follow-up period.

Isquemia e reperfusão de músculo sóleo de ratos sob ação da pentoxífilina / Ischemia and reperfusion of the soleus muscle of rats with pentoxifylline

Contexto: A reperfusão de músculo esquelético piora as lesões ja presentes no período de isquemia, pois a produção de espécies reativas de oxigênio, associadas à intensa participação de neutrófilos, amplia a reação inflamatória que induz alterações teciduais. Objetivo: Avaliar as alterações morfológicas e imuno-histoquímicas de músculo esquelético (sóleo) de ratos submetidos a isquemia e reperfusão com pentoxifilina. Métodos: Sessenta ratos foram submetidos a isquemia do membro pélvico, por 6 horas, pelo clampeamento da artéria ilíaca comum esquerda. Após isquemia, os animais do grupo A(n igual a 30) foram observados por 4 horas, e os do grupo B(n igual a 30), por 24 horas. Seis animais constituiram o grupo simulado. Administrou-se pentoxifilina apenas no período de reperfusão em A2(n igual 100) e B2(n igual 10) e nos períodos de isquemia e reperfusão em A3(n igual 10) e B3(n igual 10). O músculo sóleo foi avaliado por análise histológica (dissociação de fibras, infiltrado leucocitário, necrose) e imuno histoquímica (apoptose pela extensão da caspase-3). Foram...

Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy

Type II reaction in leprosy, or erythema nodosum leprosum (ENL), is often characterized by severe clinical symptoms together with nerve function impairment leading to permanent disabilities. Thalidomide has been shown to be a highly effective drug for the treatment of ENL. It is, however, contraindicated for women of childbearing age due to its teratogenicity. On the other hand, pentoxifylline, used to treat hypercoagulable states, is not teratogenic and, like thalidomide, can inhibit the synthesis of tumor necrosis factor-a and other cytokines. In the present randomized double-blind clinical study we compared the effectiveness of orally administered pentoxifylline vs thalidomide in treating type II reaction in 44 patients. Daily doses of 300 mg thalidomide or 1.2 g pentoxifylline were administered for 30 days to multibacillary leprosy patients undergoing type II reaction. Randomly chosen patients were included in the study before, during, and after specific multidrug therapy. Clinical evaluations were performed on the 1st, 7th, 14th, 21st, and 30th days of treatment and laboratory tests were carried out on the 1st and 30th days. As expected, overall, thalidomide proved to be more effective in the treatment of type II leprosy reaction. Nevertheless, continuous treatment with pentoxifylline was effective in relieving the clinical signs of ENL, especially limb edema and systemic symptoms, in 62.5 percent of the patients.

Oral anti platelet drugs in dermatology

An up-to-date overview of antithrombotic drugs, with their currently reported beneficial cutaneous effects and skin side effect, is presented. Attempts to balance traditional pharmacodynamic concepts with the newly described empiric benefits are made. A concise, current and useful reference for dermatologists with an interest in dermatopharmacology and the practicing physician in the field of wound care, vasculitides and skin involvement of internal diseases is tried to be achieved

The Hematologic Response to Anti-apoptotic Cytokine Therapy: Results of Pentoxifylline, Ciprofloxacin, and Dexamethasone Treatment for Patients with Myelodysplastic Syndrome

TNF-alpha mediated apoptosis of the hematopoietic cells has been thought to contribute to the ineffective hematopoiesis observed in myelodysplastic syndrome (MDS). The combination of pentoxifylline (P) and ciprofloxacin (C) has been shown to reduce the serum levels of TNF-alpha, and an earlier trial of P and C with dexamethasone (D) provided good palliation for patients with MDS. The purpose of this study is to assess the hematologic response to PCD therapy for patients suffering with MDS. 21 of 25 patients who completed at least of 12 weeks of treatment were evaluable for the treatment efficacy. At baseline, the patient's median age was 60 yr (range: 18-75 yr). The diagnoses according to WHO classification included: RA (n=5), RCMD (n=10), RARS (n=1), RCMD/RS (n=1), RAEB (3), and CMML (n=1). 11 patients (52%) had at least single lineage response. 3 patients (11%) showed improvement of triple lineage cytopenia. There were no differences in the response rates between the FAB subtypes. The median time to response was 4 weeks (range: 2-12 weeks), and it is interesting that 9 of 11 patients who had a response remained without relapse for a median of 177 days (range: 78-634 days). These preliminary results indicate that anti-cytokine therapy with PCD is an effective and well tolerated palliative treatment for patients with MDS.

Pentoxifylline and enalapril and its effects on polycythemia induced by hypobaric hypoxia in mice

Se estudió 70 ratones Swiss macho de 3-4 meses de edad, para evaluar los efectos profilácticos y terapéuticos del analapril y la pentoxifilina en la policitemia inducida por hipoxia. Se dividió a los animales en dos grupos: grupo pentoxifilina (n=39) y grupo enalapril (n=31). Cada uno fue adicionalmente dividido en un grupo profiláctico que recibió el medicamento antes de la exposición a hipoxia hipobárica intermitente (IHH) y en un grupo terapéutico que recibió el medicamento luego de la exposición a IHH. Cada Subgrupo tuvo su respectivo control. La exposición a IHH fue realizada a través de una cámara hipobárica que simulaba una altura equivalente a 4500m, 22 horas por día. Se midió semanalmente peso y hematocrito. La evolución del peso corporal en el tiempo no mostró diferencias sustanciales entre los animales tratados y los controles en los grupos profilácticos y terapéuticos, tanto en los grupos pentoxifilina como enalapril. Hubo una disminución significativa del hematocrito a los 36 y 47 días del inicio de la profilaxis en el grupo pentoxifilina. En el grupo profiláctico enapril los hematocritos fueron significativamente menores en los animales tratados. Concluimos que ambas drogas son efectivas cuando son usadas profilácticamente antes de la exposición a IHH. Se sugiere que las drogas podrían ejercer su efecto a través de un bloqueo parcial de la producción de eritropoyetina (EPO).

Neutropenia por pentoxifilina, reporte de un caso / Pentoxifyline induced neutropenia, report a case

Se reporta un caso de neutropenia causada por Pentoxifilina. Se trata de una paciente femenina de 82 años de edad con diagnóstico de Vasculitis Necrotizante Sistémica quien se hospitalizó por síncope el 8-04-89. Ocho semanas antes de su admisión ella había comenzado tratamiento con Pentoxifilina 400 mg TID por arteriopatía periférica y úlceras en piernas. Entre sus exámenes complementarios de ingres****************************************************************00190100020000220100017000420100021000590100028000800100017001080120180001250130113003050140006004180300019004240310003004430320004004460380005004500380004004550400003004590410003004620410003004650640014004680650009004820900002004910910009